Lantheus
LNTH
Collegium Pharmaceutical
COLL
Constellation Brands
STZ
Halozyme Therapeutics
HALO
AIRPORTS OF THAILAND PUBLIC CO UNSP ADR EACH REP 10 ORD SHS
AIPUY
(FY)Dec 31, 2024 | (Q4)Dec 31, 2024 | (Q3)Sep 30, 2024 | (Q2)Jun 30, 2024 | (Q1)Mar 31, 2024 | (FY)Dec 31, 2023 | (Q4)Dec 31, 2023 | (Q3)Sep 30, 2023 | (Q2)Jun 30, 2023 | (Q1)Mar 31, 2023 | |
---|---|---|---|---|---|---|---|---|---|---|
Operating Cash Flow (Indirect Method) | ||||||||||
Cash flow from continuing operating activities | -119.02%-132M | -415.15%-170M | -94.18%11M | -72.69%62M | -111.25%-35M | 62.53%694M | -118.13%-33M | 48.82%189M | 183.75%227M | 718.42%311M |
Net income from continuing operations | 326.24%957M | 96.55%-11M | 945.31%1.08B | -556.25%-73M | -612.50%-41M | -816.95%-423M | -1,672.22%-319M | -285.51%-128M | -62.79%16M | 122.86%8M |
Operating gains losses | -3,202.13%-1.55B | -76.47%16M | -1,338.89%-1.55B | -16.67%-7M | -600.00%-7M | -4,600.00%-47M | 1,460.00%68M | -5,500.00%-108M | ---6M | -150.00%-1M |
Depreciation and amortization | -46.87%297M | -38.78%60M | -54.84%70M | -44.52%86M | -46.36%81M | -8.36%559M | -38.36%98M | 1.97%155M | 1.97%155M | 2.72%151M |
Deferred tax | -69.29%43M | 152.46%32M | -89.78%19M | -255.56%-14M | 0.00%6M | 133.33%140M | -269.44%-61M | 933.33%186M | 350.00%9M | 50.00%6M |
Change In working capital | -76.79%65M | -378.22%-281M | 695.83%382M | 218.75%51M | -175.65%-87M | 165.73%280M | 539.13%101M | 133.80%48M | 110.96%16M | 200.00%115M |
-Change in receivables | -221.28%-57M | -24.71%-106M | -133.33%-12M | 41.94%44M | -73.85%17M | 121.76%47M | -246.55%-85M | 155.38%36M | 138.75%31M | 150.39%65M |
-Change in inventory | 333.33%39M | -90.48%2M | 118.18%6M | -53.03%31M | --0 | 104.79%9M | -34.38%21M | -83.33%-33M | 152.80%66M | 41.56%-45M |
-Change in payables and accrued expense | -206.48%-115M | -181.32%-74M | -90.91%11M | 107.26%9M | -405.00%-61M | 272.41%108M | 208.33%91M | 120.00%121M | -202.48%-124M | 131.75%20M |
-Change in other working capital | 70.69%198M | -239.19%-103M | 596.05%377M | -176.74%-33M | -157.33%-43M | 327.45%116M | 355.17%74M | 33.33%-76M | 169.35%43M | -51.30%75M |
Cash from discontinued investing activities | ||||||||||
Operating cash flow | -119.02%-132M | -415.15%-170M | -94.18%11M | -72.69%62M | -111.25%-35M | 62.53%694M | -118.03%-33M | 50.00%189M | 170.24%227M | 814.71%311M |
Investing cash flow | ||||||||||
Cash flow from continuing investing activities | 854.83%2.19B | 1,046.67%172M | 1,990.09%2.1B | 75.00%-27M | 37.21%-54M | 25.06%-290M | 116.85%15M | 8.26%-111M | -18.68%-108M | 0.00%-86M |
Capital expenditure reported | 42.44%-217M | 45.07%-39M | 48.04%-53M | 47.11%-64M | 26.51%-61M | 0.00%-377M | 19.32%-71M | 11.30%-102M | -28.72%-121M | -3.75%-83M |
Net PPE purchase and sale | --0 | --0 | --0 | ---- | ---- | -20.00%8M | --0 | --0 | ---- | ---- |
Net business purchase and sale | 2,661.80%2.46B | --0 | 244,300.00%2.44B | 40.00%7M | 333.33%7M | 693.33%89M | 2,966.67%86M | 109.09%1M | --5M | -200.00%-3M |
Net investment purchase and sale | --0 | --0 | ---- | ---- | ---- | ---10M | --0 | ---- | ---- | ---- |
Net other investing changes | ---52M | --211M | ---293M | ---- | ---- | ---- | ---- | ---- | ---- | ---- |
Cash from discontinued investing activities | ||||||||||
Investing cash flow | 854.83%2.19B | 1,046.67%172M | 1,990.09%2.1B | 75.00%-27M | 37.21%-54M | 25.06%-290M | 116.85%15M | 8.26%-111M | -18.68%-108M | 0.00%-86M |
Financing cash flow | ||||||||||
Cash flow from continuing financing activities | -85.94%-1.56B | 97.65%-64M | -170.44%-1.51B | 28.57%-65M | 145.71%80M | -84,000.00%-839M | -2,854.35%-2.72B | 2,045.00%2.15B | -1,037.50%-91M | -17,600.00%-175M |
Net issuance payments of debt | -1,360.78%-1.49B | 99.60%-8M | -170.45%-1.51B | 27.96%-67M | 157.14%92M | -234.21%-102M | -3,448.21%-1.99B | 1,956.73%2.14B | -9,200.00%-93M | -655.17%-161M |
Net common stock issuance | ---56M | ---- | ---- | ---- | ---- | --0 | ---- | ---- | ---- | ---- |
Cash dividends paid | 0.00%-15M | 25.00%-3M | -33.33%-4M | 0.00%-4M | 0.00%-4M | 0.00%-15M | 0.00%-4M | 0.00%-3M | 0.00%-4M | 0.00%-4M |
Proceeds from stock option exercised by employees | -51.85%13M | -25.00%3M | -66.67%3M | -12.50%7M | --0 | -12.90%27M | -66.67%4M | 80.00%9M | 0.00%8M | 0.00%6M |
Net other financing activities | 98.40%-12M | --0 | ---3M | 50.00%-1M | 50.00%-8M | -723.08%-749M | -1,561.36%-731M | --0 | 81.82%-2M | 46.67%-16M |
Cash from discontinued financing activities | ||||||||||
Financing cash flow | -85.94%-1.56B | 97.65%-64M | -170.44%-1.51B | 28.57%-65M | 145.71%80M | -84,000.00%-839M | -2,854.35%-2.72B | 2,045.00%2.15B | -1,037.50%-91M | -17,600.00%-175M |
Net cash flow | ||||||||||
Beginning cash position | -61.49%285M | -72.62%825M | -71.36%232M | -65.51%269M | -61.49%285M | -1.20%740M | 304.43%3.01B | 21.99%810M | 12.72%780M | -1.20%740M |
Current changes in cash | 214.25%497M | 97.73%-62M | -73.10%598M | -207.14%-30M | -118.00%-9M | -1,160.98%-435M | -136,900.00%-2.74B | 2,017.14%2.22B | 286.67%28M | 198.04%50M |
Effect of exchange rate changes | -20.00%-24M | -162.50%-5M | 75.00%-5M | -450.00%-7M | 30.00%-7M | 60.00%-20M | 214.29%8M | 16.67%-20M | 115.38%2M | -66.67%-10M |
End cash Position | 165.96%758M | 165.96%758M | -72.62%825M | -71.36%232M | -65.51%269M | -61.49%285M | -61.49%285M | 304.43%3.01B | 21.99%810M | 12.72%780M |
Free cash flow | -210.09%-349M | -100.96%-209M | -148.28%-42M | -101.89%-2M | -142.11%-96M | 534.00%317M | -209.47%-104M | 690.91%87M | 1,160.00%106M | 595.65%228M |
Currency Unit | USD | USD | USD | USD | USD | USD | USD | USD | USD | USD |
Accounting Standards | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP |
Audit Opinions | Unqualified Opinion | -- | -- | -- | -- | Unqualified Opinion | -- | -- | -- | -- |